Table 1

Characteristics of the population at inclusion (n=84)

CharacteristicsValues
Age (years)61.5 (49.5:71)
Female sex62 (73.8)
Ethnicity
Caucasian81 (96.4)
African1 (1.2)
Maghrebian2 (2.4)
BMI (kg/m2)26.1 (22.7:30.1)
Number of treatments per day3 (1:5)
Number of tablets per day3 (1:5)
Comorbidities (Charlson Score)3 (2:5)
Immunopositivity (CCP and/or RF)63 (75)
Disease duration (months)130.5 (41:202.5)
Duration of MTX treatment (months)94.5 (27:164)
MTX dose (mg/week)15 (11.2:20)
MTX administration mode
PO26 (30.9)
SC58 (69.1)
Biologic therapy at inclusion52 (61.9)
Usual follow-up
Outpatient consultation51 (60.7)
Day hospitalisation33 (39.3)
RA activity at inclusion
Remission47 (55.9)
Low10 (11.9)
Moderate22 (26.2)
High5 (5.9)
DAS28-CRP at inclusion2.38 (1.75:3.72)
CRP (mg/L)4 (1:8.4)
Albumin (g/L)*41.1 (39.3:44)
MCV (fL)94 (91:96)
  • Qualitative variables are expressed as frequency (%), and quantitative variables are expressed as median (Q1:Q3). RA activity was determined based on the DAS-CRP value at inclusion.

  • *10 missing data.

  • BMI, body mass index; CCP, Cyclic Citrullinated Peptides; CRP, C reactive protein; DAS28, Disease Activity Score-28; MCV, mean corpuscular volume; MTX, methotrexate; PO, oral; RA, rheumatoid arthritis; RF, Rheumatoid Factor; SC, subcutaneous.